177 related articles for article (PubMed ID: 22153981)
1. The state of therapy for removal of alloantibody producing plasma cells in transplantation.
Everly MJ; Terasaki PI
Semin Immunol; 2012 Apr; 24(2):143-7. PubMed ID: 22153981
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
Woodle ES; Alloway RR; Girnita A
Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
[TBL] [Abstract][Full Text] [Related]
3. Elimination of post-transplant donor-specific HLA antibodies with bortezomib.
Idica A; Kaneku H; Everly MJ; Trivedi HL; Feroz A; Vanikar AV; Shankar V; Trivedi VB; Modi PR; Khemchandani SI; Dave SD; Terasaki PI
Clin Transpl; 2008; ():229-39. PubMed ID: 19708459
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibition for antibody-mediated rejection.
Everly JJ; Walsh RC; Alloway RR; Woodle ES
Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989
[TBL] [Abstract][Full Text] [Related]
5. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
Stuckey LJ; Kamoun M; Chan KM
Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
[TBL] [Abstract][Full Text] [Related]
6. Abrogation of anti-HLA antibodies via proteasome inhibition.
Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
[TBL] [Abstract][Full Text] [Related]
7. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo.
Diwan TS; Raghavaiah S; Burns JM; Kremers WK; Gloor JM; Stegall MD
Transplantation; 2011 Mar; 91(5):536-41. PubMed ID: 21283064
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Tevar A; Woodle ES
Transplantation; 2008 Dec; 86(12):1754-61. PubMed ID: 19104417
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.
Govil A; Walsh RC; Tevar A; Alloway R; Roy-Chaudhury P; Mogilishetty G; Wall GE; Brailey P; Girnita A; Woodle ES
Clin Transpl; 2009; ():443-53. PubMed ID: 20524313
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitor therapy for antibody-mediated rejection.
Woodle ES; Walsh RC; Alloway RR; Girnita A; Brailey P
Pediatr Transplant; 2011 Sep; 15(6):548-56. PubMed ID: 21884344
[TBL] [Abstract][Full Text] [Related]
12. Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series.
Lachmann N; Schütz M; Budde K; Schönemann C; Waiser J
Clin Transpl; 2009; ():351-8. PubMed ID: 20527073
[TBL] [Abstract][Full Text] [Related]
13. Use of bortezomib for prevention and treatment of rejection in sensitized patients.
Hartono C; Lubetzky M; Aull MJ; Saal S; Figueiro J; Kapur S; Dadhania D
Clin Transpl; 2009; ():499-503. PubMed ID: 20524323
[TBL] [Abstract][Full Text] [Related]
14. Antibody-mediated rejection in kidney transplantation: an update.
Lucas JG; Co JP; Nwaogwugwu UT; Dosani I; Sureshkumar KK
Expert Opin Pharmacother; 2011 Mar; 12(4):579-92. PubMed ID: 21294653
[TBL] [Abstract][Full Text] [Related]
15. Targeting alloantibody production with bortezomib: does it make more sense?
Lee I; Constantinescu S; Gillespie A; Rao S; Silva P; Birkenbach M; Leech S; Karachristos A; Daller JA; Sifontis NM
Clin Transpl; 2010; ():397-403. PubMed ID: 21696057
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL
Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition reduces donor-specific antibody levels.
Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Brown E; Tevar A; Woodle ES
Transplant Proc; 2009; 41(1):105-7. PubMed ID: 19249489
[TBL] [Abstract][Full Text] [Related]
18. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.
Flechner SM; Fatica R; Askar M; Stephany BR; Poggio E; Koo A; Banning S; Chiesa-Vottero A; Srinivas T
Transplantation; 2010 Dec; 90(12):1486-92. PubMed ID: 21042239
[TBL] [Abstract][Full Text] [Related]
19. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J
J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130
[TBL] [Abstract][Full Text] [Related]
20. Rescue therapy for early antibody mediated rejection with a proteasome inhibitor: a case report.
Manitpisitkul W; Wilson N; Cooper M; Gurk-Turner C; Hurley H; Rasetto F; KuKuruga D; Barth RN; Philosophe B
Clin Transpl; 2009; ():461-3. PubMed ID: 20524315
[No Abstract] [Full Text] [Related]
[Next] [New Search]